vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and Alzheimer’s disease, today announced that it is scheduled to present a general company update at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 10:50 a.m. Eastern Time in New York City. Company management will also be meeting with members of the investment community during one-on-one meetings at the conference.

A live webcast of the presentation can be accessed here and will be accessible for 30 days following the presentation at www.vtvtherapeutics.com.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes, Alzheimer’s disease, and inflammatory disorders. vTv’s development partners are pursuing additional indications in type 2 diabetes, COPD, and genetic mitochondrial diseases.

ContactsInvestors: vTv Therapeutics Inc. IR@vtvtherapeutics.com

or Media:Glenn SilverLazar FINN Partners646-871-8485gsilver@lazarpartners.com

vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more vTv Therapeutics Charts.
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more vTv Therapeutics Charts.